Global Health Investment Fund
Our namesake $108 million social impact fund (GHIF) invested in twelve companies developing clinical diagnostics, devices, vaccines, and therapeutics targeting diseases that disproportionately burden people living in low- and middle-income countries, such as HIV/AIDS, malaria, tuberculosis and cholera. The fund’s portfolio companies have successfully commercialized more than a dozen products that have been delivered to over 500 million people.
GHIF's financial performance has demonstrated that it is possible to generate meaningful financial returns by investing public, philanthropic, and private capital in global health product development.
The Global Health Investment Fund focused on a wide range of infectious diseases and maternal/infant health conditions, including HIV/AIDS, malaria, tuberculosis, cholera, chikungunya, river blindness, and pre-eclampsia. Increasing access to existing products and interventions has also been part of GHIF's mission. Most recently, several of the GHIF companies launched successful COVID-19 programs.
The innovative investment model pioneered by GHIC through its Global Health Investment Fund has also stimulated the launch of additional investment funds seeking to build upon this model and further magnify its impact.
"The private sector has all the tools to do the job. What is required is an innovative spirit, and a willingness to be as bold in the social arena as corporations are in the marketplace." – Jamie Dimon, Chairman and CEO, JP Morgan Chase & Co.
Portfolio Investments
Access Bio . Opens in new tab.
Global Health Investment Fund
Intervention: Diagnostic
Targets: Malaria, G6PDd, HIV, dengue, HPV, Zika
Impact Objectives: Reduced cost of high-quality malaria RDTs; new, low-cost diagnostics for other diseases
Alydia Health . Opens in new tab.
Global Health Investment Fund
Intervention: Device
Targets: Postpartum hemorrhage
Impact Objectives: Develop new gold-standard intervention for PPH
Atomo Diagnostics . Opens in new tab.
Global Health Investment Fund
Intervention: Diagnostic
Targets: HIV, Ebola, HCV, malaria
Impact Objectives: Improved professional testing and self-testing
BD . Opens in new tab.
Global Health Investment Fund
Intervention: Diagnostic
Targets: Preeclampsia (PE), gestational diabetes mellitus (GDM)
Impact Objectives: Early, affordable, point-of-care PE/GDM testing; ↓ maternal/infant mortality/morbidity
EUBiologics . Opens in new tab.
Global Health Investment Fund
Intervention: Vaccine
Targets: Cholera
Impact Objectives: Increase global supply of affordable vaccine doses; deliver improved presentation at $1/dose
Genedrive . Opens in new tab.
Global Health Investment Fund
Intervention: Diagnostic
Targets: Tuberculosis (TB), HCV
Impact Objectives: Diagnosis of TB and HCV on a near-point-of-care molecular diagnostic platform, enabling more effective treatment
IanTech . Opens in new tab.
Global Health Investment Fund
Intervention: Surgical device
Targets: Cataract-induced blindness and visual impairment
Impact Objectives: Expand access to vision-restoring cataract surgery in resource-limited settings
Moxidectin . Opens in new tab.
Global Health Investment Fund
Intervention: Treatment
Targets: Onchocerciasis (river blindness)
Impact Objectives: Accelerate the eradication of onchocerciasis; improve treatment outcomes
PATH . Opens in new tab.
Global Health Investment Fund
Intervention: Treatment
Targets: Hookworm, Roundworm, Whipworm
Impact Objectives: Cure hundreds of millions of school-aged children from parasitic worm infections; expand the arsenal of anthelmintics
Serum Institute . Opens in new tab.
Global Health Investment Fund
Intervention: Vaccines and therapeutics
Targets: Anti-venom for snakebites, vaccines for tuberculosis and pertussis
Impact Objectives: High-quality anti-venoms, increased access to Tdap vaccines in pregnancy, more effective protection against tuberculosis
Themis Bioscience . Opens in new tab.
Global Health Investment Fund
Intervention: Vaccine platform
Targets: Chikungunya, Zika
Impact Objectives: Protect at-risk communities from public health challenges such as mosquito-transmitted viruses
Univercells . Opens in new tab.
Global Health Investment Fund
Intervention: Biologics manufacturing technology platform
Targets: Polio, Measles, Rubella
Impact Objectives: Dramatic reductions in the cost of essential biologics; distributed manufacturing